NanoViricides, Inc. (NNVC)


-0.02 (-1.56%)
Symbol NNVC
Price $1.26
Beta 1.157
Volume Avg. 0.10M
Market Cap 14.699M
Shares () -
52 Week Range 1.04-2.0
1y Target Est -
DCF Unlevered NNVC DCF ->
DCF Levered NNVC LDCF ->
ROE -31.60% Strong Sell
ROA -35.19% Strong Sell
Operating Margin -
Debt / Equity -
P/E -2.03 Sell
P/B 0.80 Buy


Consensus EPS

Upgrades & Downgrades

Latest NNVC news

Dr. Anil R. Diwan Ph.D.
American Stock Exchange

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.